80% Breast Cancer Recurrence Reduction: Greenwich's GLSI-100 Immunotherapy Gets FDA Fast Track Boost

GLSI-100 Gets FDA Fast Track Designation for Breast Cancer

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover its potential benefits.

FDA Fast Tracks Vaccine For Some With Breast Cancer

The FDA has granted fast track designation to the cancer vaccine GLSI-100 for patients with HLA-A*02-positive and HER2-positive breast cancer.

FDA grants Greenwich fast track designation for GLSI-100 - BioTuesdays

Greenwich LifeSciences (NASDAQ: GLSI) announced that the FDA has granted GLSI-100 fast track designation for the treatment of patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed treatment with standard of care HER2/neu targeted therapy. According to Greenwich, this designation may lead to earlier drug approval as the company and the FDA can communicate more frequently to expedite the Biologic License Application (B…

Release - Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation - Channelchek

Open the article to view the coverage from channelchek.com

80% Breast Cancer Recurrence Reduction: Greenwich's GLSI-100 Immunotherapy Gets FDA Fast Track Boost

FDA grants Fast Track status to GLSI-100 for HER2+ breast cancer patients after Phase IIb showed 80% recurrence reduction. No serious adverse events in 146 patients over 5 years.